PROTEASE inhibitors have been shown to inhibit tumour growth (Latner et al., 1974; Verloes et al., 1978) and invasiveness (Latner et al., 1973) in animal model systems. In addition, other recent evidence (Latner & Turner, 1976; Burden et al., 1978) has suggested that these substances may be operating in cancer by stimulating the host's immunological response. In view of these observations, we decided to investigate the in vitro effect of the protease inhibitor aprotinin (Trasylol®) on the response to PPD (purified protein derivative of Mycobacterium tuberculosis) of human peripheral lymphocytes from cancer patients and from non-tumour-bearing individuals using the Tanned Erythrocyte Electrophoretic Mobility (TEEM) test (Shenton et al., 1977) .
Heparinized venous blood was obtained from 4 groups of individuals. The 1st group ("Healthy") consisted of 10 volunteers who were clinically fit. The 2nd group ("Post-Operative") consisted of 6 patients who had undergone moderate intra-abdominal surgery 10 days previously for benign conditions. The 3rd group ("Operable Carcinoma") consisted of 7 patients who had undergone a "curative" resection of an adenocarcinoma of the stomach with removal of all macroscopic tumour. The 4th group ("Inoperable Carcinoma") consisted of 9 patients who had a carcinoma of the stomach which at laparotomy had been unresectable. Blood specimens were withdrawn in the latter two groups 5-0 days after operation.
Peripheral lymphocytes were isolated from whole blood using the densitygradient centrifugation technique described by Boyum (1968 (Shenton et al., 1977) . Differences between groups were analysed statistically using Student's t test.
At the concentration of aprotinin used in these studies (3.3 u/ml) no significant change in erythrocyte mobility could be detected either after incubating the erythrocytes directly with the aprotinin or after treating the erythrocytes with supernatant from lymphocytes which had been treated with aprotinin only. Table I shows the TEEM-test results for peripheral lymphocytes exposed to PPD. Lymphocytes from "Healthy" individuals produced the greatest response, viz. greatest % S. For all the other groups, the response was diminished, and significantly less than in the healthy group. Comparison of the "Post-Operative" and "Operable Carcinoma" groups indicated no significant difference (P > 0 05). However, the response of the "Post-Operative" group was significantly lower (P < 0 025) than that of the "Inoperable Carcinoma" group. Table II shows the 'TEEM test' results for peripheral lymphocytes exposed to PPD and aprotinin. In all groups, the inclusion of aprotinin significantly increased the response of lymphocytes to PPD (P < 0.05). This effect was least mean s.e. P 37-1 4-5 43-6 6-7 88-4 10-6 65-6 9 3 >0*05 < 0 *0005 <0-01 * Calculated for each individual using the following formula:
(Oo SPPD + Aprotinin) -% SPPD X 100 % SPPD Table III combines the data in Tables  I and II and gives the percentage increase in lymphocyte response to PPD produced by treatment with aprotinin. It can be seen that the percentage increases for the "Healthy" and "Post-Operative" groups are not significantly different. On the other hand, in both "Carcinoma" groups the percentage increase is very significantly higher than in the "Healthy" group.
Our results indicate that aprotinin can considerably stimulate the response to PPD of peripheral lymphocytes from cancer patients. This stimulation was shown to be more a process of restoration to normal levels of a depressed immunological response than a specific stimulation of the cancer lymphocytes. Both surgical trauma and/or the presence of cancer resulted in lymphocyte depression in the TEEM test in the absence of aprotinin. This confirms findings from other studies with different techniques (Riddle & Berenbaum, 1967; Turnbull & Cooper, 1975) . Although these two conditions produce the same end result they do not appear, from our data, to achieve it by a similar mechanism. Firstly, depressive effects were not additive, because the mean % S for the "Operable Carcinoma" group, in which surgical trauma was considerable, was not less than that in the "Post-Operative" group. Secondly, the aprotinin -stimulated response of the "Post-Operative" group was much less than that of the cancer groups, and even less than that of untreated "Healthy" lymphocytes. In other words, aprotinin treatment did not restore "Post-Operative" lymphocytes to a normal functional level, as judged by the TEEM test, whereas cancer lymphocytes were completely restored.
The precise role of protease inhibitors in lymphocyte stimulation is still very unclear. Our findings of general stimulation by aprotinin treatment support those recently reported by Burden et al. (1978) using the leucocyte migration test. In contrast, Hirschhorn et al. (1971) have reported inhibition by several synthetic protease inhibitors, including EACA, of a number of parameters associated with lymphocyte stimulation. It may be that the effect of aprotinin on lymphocytes is dose dependent. To support this idea, published data (Thomson et al., 1978) have shown that aprotinin, at concentrations of the same order that we have used, slightly stimulates PHA and ConA-activated lymphocyte transformation as measured by [3H] TdR incorporation, whereas at higher concentrations the effect appears to be one of inhibition.
